Meta-analysis of the Efficacy and Safety of Anti-vascular Endothelial Growth Factor Inhibitor in the Treat-ment of Retinopathy of Prematurity
10.6039/j.issn.1001-0408.2016.24.21
- VernacularTitle:血管内皮生长因子抑制剂治疗早产儿视网膜病变有效性和安全性的Meta分析Δ
- Author:
Zhiqiang HU
;
Lingli ZHANG
;
Jialian LI
;
Zuojie ZHANG
;
Linan ZENG
;
Jing SHI
;
Shuyan QUAN
- Publication Type:Journal Article
- Keywords:
Retinopathy of prematurity;
Anti-vascular endothelial growth factor inhibitor;
Meta-anaylsis
- From:
China Pharmacy
2016;27(24):3377-3379
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the efficacy and safety of anti-vascular endothelial growth factor(VEGF)in-hibitors in the treatment of retinopathy of prematurity (ROP),and provide evidence-based reference for clinic. METHODS:Re-trieved from PubMed,EMBase,Cochrane Library,CJFD,VIP,CBM and Wangfang Database,randomized controlled trials (RCT) about VEGF inhibitors (test group) versus laser photocoagulation treatment (control group) in the treatment of ROP were collected. Meta-analysis was performed by using Rev Man 5.1 software after data extraction and quality evaluation by Cochrane re-viewers manual 5.1.0. RESULTS:Totally 5 RCTs were included,involving 381 infants and 754 eyes.Results of Meta-analysis showed that the recurrence rate of ROP [RR=0.23,95%CI(0.13,0.42),P<0.001],retinal detachment incidence [RR=0.27,95%CI(0.14,0.51),P<0.001] andresolution of plus signs [MD=-1.31,95%CI(-1.47,-1.14),P<0.001] in test group were signifi-cantly lower than control group,the differences were statistically significant;and there was no significant difference in the refrac-tive errors and the incidence of adverse reactions in 2 groups(P>0.05). CONCLUSIONS:Intravitreal VEGF inhibitors have better efficacy than laser photocoagulation in the treatment of ROP,but the optimal dose and safety need further verification by large-sam-ple and well-designed RCT.
